Eli Lilly And Company (NYSE:LLY) stock is trading lower on Wednesday. The company is anticipated to release 2024 fiscal year earnings on Thursday before the market opens.
What To Know: Analyst estimates EPS of $2.70 and sales of $9.94 billion.
For the previous fiscal quarter, Eli Lilly missed analyst estimates regarding revenue by 1.7% but beat analyst EPS estimates by 4.88%. Eli Lilly beat analyst estimates for EPS for the last four earnings reports. The company missed analyst EPS estimates by 6.36% for the 2023 fiscal year first quarter.
What Else: Eli Lilly's weight-loss drug Zepbound has gained traction in the market following its December launch, capturing about 40% of the market. As of mid-July, 130,000 prescriptions of Eli Lilly's Zepbound were filled weekly versus 200,000 for Novo Nordisk A/S's (NYSE:NVO) Wegovy.
Analyst Changes: Within the past week, multiple analysts have issued price target adjustments.
- Cantor Fitzgerald analyst Louise Chen reiterated Eli Lilly with a Overweight and maintained $885 price target.
- Guggenheim analyst Seamus Fernandez maintained Eli Lilly with a Buy and raised the price target from $855 to $884.
How To Buy Eli Lilly and Company Stock
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Eli Lilly (NYSE:LLY)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: CVS Health Reports Mixed Q2 Earnings, Lowers 2024 Outlook, Reshuffles Segment Management
LLY Price Action: Eli Lilly shares are trading 2.73% lower at $771.50 at the time of publication, according to data from Benzinga Pro.
Image: Photo by rafapress on Shutterstock
Eli Lilly（纽交所：LLY）股票周三下跌交易。该公司预计将在周四开盘前发布2024财年财报。
了解更多：分析师预计每股收益为2.7美元，销售额为994亿美元。
对于上一财季，Eli Lilly在营业收入方面未能达到分析师的预期，但超过了每股收益的分析师预期。Eli Lilly在过去的四个财报中每股收益超过了分析师预期。该公司2023财年第一季度每股收益未能达到分析师预期的值下降了6.36%。
此外：自12月份推出以来，Eli Lilly的减肥药Zepbound在市场上受到了广泛的关注，占据了约40%的市场份额。截至7月中旬，每周有13万份Eli Lilly的Zepbound处方被填写，相比之下诺和诺德（纽交所：NVO）的Wegovy处方每周有20万份。
分析师调整：在过去一周内，多位分析师已发布价格目标调整。
- 康泰瑞银行的分析师Louise Chen reiterates Eli Lilly为超配，维持885美元的价格目标。
- 古根海姆证券的分析师Seamus Fernandez 维持Eli Lilly为买入，将价格目标从855美元上调至884美元。
如何购买礼来公司（Eli Lilly and Company）的股票
除了手动到经纪所平台购买股票或者部分股票，您还可以通过购买持有股票的ETF，或者在401(k)中分配资金进入一项该类基金或其他工具的策略来获得股票的份额。例如，Coinbase属于金融部门。ETF通常持有许多能跟踪该部门的流动性和大型公司的股票，使投资者能够获得该股票板块内的趋势。
例如，在Eli Lilly（纽交所：LLY）的案例中，它属于医疗保健板块。ETF可能会持有许多液体和大型公司的股份，以帮助追踪该板块，从而使投资者获得该领域内的市场趋势曲线。
相关链接：CVS Health报告Q2财报混合，下调2024展望，重组部门管理。
LLY股价表现：根据Benzinga Pro的数据，该股票价格为771.50美元，较发表时间下跌2.73%。
图片：来自Shutterstock的rafapress摄影
